Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Libramont-Chevigny

16 clinical trials in Libramont-Chevigny, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Libramont-Chevigny at a glance
16
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

16 trials in Libramont-Chevigny

Open in trial search

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trilaciclib dihydrochloride
  • Sponsor:Pharmacosmos A/S

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AZD5335
  • Sponsor:AstraZeneca AB

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Boehringer Ingelheim International GmbH

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

Embolism

Not yet recruiting

A study to evaluate the effectiveness of REGN7508 for preventing blood clots in adults with solid tumors undergoing cancer treatment.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 S228P Monoclonal Antibody Against Factor Xi And Activated Factor Xi
  • Sponsor:Regeneron Pharmaceuticals Inc.

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Exelixis Inc.

Study Comparing Datopotamab Deruxtecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GAD20-209-FSP-A1
  • Sponsor:Nouscom S.r.l.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Libramont-Chevigny

What the registry says about research in the country

01 Oncology (Neoplasms)

Trials in Libramont‑Chevigny are evaluating new therapies for advanced platinum‑resistant epithelial ovarian cancer, high‑risk non‑muscle‑invasive bladder cancer, limited‑stage small cell lung cancer, as well as gastrointestinal and head‑and‑neck malignancies, with the aim of extending progression‑free and overall survival.

  • Novel immunotherapy combinations
  • Targeted agents based on tumor biomarkers
  • Comparative effectiveness of emerging drugs versus standard care
  • Strategies to prevent disease recurrence

These studies seek to bring innovative treatments to patients with aggressive cancers and to define next‑generation standards of care.

02 Cancer‑Associated Thrombosis (Hemic & Lymphatic)

A dedicated trial is assessing the ability of REGN7508 to prevent cancer‑associated thrombosis and reduce bleeding complications in individuals receiving cancer therapy, reflecting a focus on vascular safety alongside oncologic treatment.

  • Prevention of venous thromboembolism in solid tumour patients
  • Evaluation of bleeding risk management
  • Integration of antithrombotic therapy with chemotherapy
  • Impact on overall treatment outcomes

The project aims to improve supportive care by lowering clot‑related events that can interrupt cancer treatment.

03 Prostate Cancer (Male Urogenital)

Research tests the addition of sarup​arib (AZD5305) to radiation and androgen‑deprivation therapy for men with high‑risk or very high‑risk localized prostate cancer carrying a BRCA mutation, targeting metastasis‑free survival.

  • Combination of targeted PARP inhibition with standard radiotherapy
  • Assessment of metastasis‑free survival benefits
  • Genetic stratification of patients based on BRCA status
  • Evaluation of safety and tolerability in combination regimen

The goal is to personalize treatment for genetically defined high‑risk prostate cancer and reduce the chance of disease spread.

04 Symptom Management & Pathological Conditions

Some studies address broader pathological conditions, focusing on preventing myelosuppression with agents like trilaciclib during chemoradiation for limited‑stage small cell lung cancer, thereby protecting blood cell counts and improving quality of life.

  • Myelosuppression prevention during chemoradiotherapy
  • Maintenance of hematologic health during intensive treatment
  • Impact on patient‑reported outcomes
  • Potential to enable full treatment dosing

These investigations support better tolerability of aggressive cancer regimens, benefiting patients across multiple tumour types.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.